Nokea
Which of the following is a chronic lung disease that includes conditions such as chronic bronchitis and emphysema, characterized by obstructed airflow from the lungs?
- A. Chronic obstructive pulmonary disease (COPD)
- B. Pulmonary fibrosis
- C. Asthma
- D. Pneumonia
Correct Answer: A
Rationale: The correct answer is A: Chronic obstructive pulmonary disease (COPD). COPD is characterized by chronic bronchitis and emphysema, leading to obstructed airflow from the lungs. Chronic bronchitis involves inflammation of the bronchial tubes, while emphysema damages the air sacs in the lungs. Pulmonary fibrosis (B) is scarring of lung tissue, not obstructed airflow. Asthma (C) is a condition where airways narrow and swell, not necessarily leading to obstructed airflow. Pneumonia (D) is an infection in the lungs, not a chronic disease causing obstructed airflow.
You may also like to solve these questions
What is the term for inflammation of the bronchial tubes, often leading to a persistent cough and mucus production?
- A. Bronchitis
- B. Asthma
- C. Pneumonia
- D. Cystic fibrosis
Correct Answer: A
Rationale: The correct answer is A: Bronchitis. Bronchitis refers to inflammation of the bronchial tubes, causing symptoms such as persistent cough and mucus production. This condition is often caused by viral or bacterial infections, irritants, or smoking. Asthma (B) is a chronic respiratory condition characterized by airway inflammation and tightening, leading to difficulty breathing. Pneumonia (C) is an infection in the lungs, typically caused by bacteria, viruses, or fungi. Cystic fibrosis (D) is a genetic disorder affecting the lungs and other organs, leading to thick mucus production and recurrent infections. Therefore, the term that specifically describes inflammation of the bronchial tubes is bronchitis, making it the correct answer in this scenario.
A client is admitted to the hospital with a dysrhythmia. Which of the following is the most common cause of dysrhythmias?
- A. Hypothermia
- B. Metabolic acidosis
- C. Drug therapy
- D. Ischemic heart disease
Correct Answer: D
Rationale: Ischemic heart disease is the leading cause of dysrhythmias due to compromised blood flow to the heart muscle.
As the cardiac-vascular nurse prepares to administer an experimental cardiac drug to a patient who is participating in a research study, the patient states that they no longer want the medication. The nurse advises the patient that:
- A. participation in the study is critical to improving the quality of patient outcomes.
- B. the medication dose has been scheduled for administration.
- C. the primary investigator will speak with the patient about their decision.
- D. they have the right to refuse the medication and to withdraw from the study.
Correct Answer: D
Rationale: Patients have the right to refuse treatment or withdraw from a study at any time.
What is a condition where the heart beats too slowly, reducing the amount of blood pumped to the body?
- A. Bradycardia
- B. Tachycardia
- C. Atrial fibrillation
- D. Ventricular fibrillation
Correct Answer: A
Rationale: Certainly! Bradycardia is the correct answer because it refers to a slow heart rate, leading to reduced blood flow to the body. This condition can result in symptoms like dizziness, fatigue, and fainting. Tachycardia, on the other hand, is the opposite - a fast heart rate that can also impact blood flow. Atrial fibrillation and ventricular fibrillation are irregular heart rhythms rather than slow heart rates, causing rapid and chaotic heartbeats that can be life-threatening. Therefore, the correct answer is A, bradycardia, as it specifically addresses the scenario of the heart beating too slowly.
When administering enoxaparin (Lovenox) to a client, what is the most important lab value to monitor?
- A. Platelet count
- B. aPTT
- C. Hemoglobin
- D. INR
Correct Answer: A
Rationale: The correct answer is A: Platelet count. When administering enoxaparin, the most important lab value to monitor is the platelet count because enoxaparin can cause thrombocytopenia, a potentially serious adverse effect. Monitoring platelet count helps to detect and prevent this complication.
Summary of other choices:
B: aPTT - Enoxaparin does not directly affect aPTT, so monitoring this value is not as critical as platelet count.
C: Hemoglobin - While monitoring hemoglobin may be important for some conditions, it is not the most crucial lab value to monitor when administering enoxaparin.
D: INR - Enoxaparin does not affect the INR, so monitoring this value is not necessary when administering this medication.